Alex Capano, DNP, CRNP, FNP-BC, is the Chief Science Officer of Ecofibre Limited, the global leader in hemp technologies that provides innovation solutions to address emerging health and resource sustainability issues.
At Ecofibre, Dr. Capano champions the company’s $40 million commitment to research to advance the clinical evidence of hemp extract. Ecofibre was the first hemp company to receive IND authorization from the FDA for research. Partnering with leading healthcare and academic institutions, Dr. Capano is currently researching CBD’s effects on CIPN, sleep, anxiety, addiction, endometriosis, certain cancers, and cognitive decline.
Dr. Capano’s recent clinical trial concluded that CBD hemp extract could reduce opioid use and improve quality of life indicators in chronic pain patients. The full manuscript is published in Postgraduate Medicine.
Dr. Capano earned her DNP at Thomas Jefferson University in Philadelphia, Pennsylvania, where she graduated Summa Cum Laude and was awarded the Sandra Festa Ryan award for Outstanding Creativity and Innovation. She was the first doctoral candidate of any discipline who focused on cannabinoid science under the guidance of the Lambert Center for the Study of Medicinal Cannabis and Hemp. Dr. Capano also holds a BSN and an MSN from the University of Pennsylvania, and a BS in neuroscience from the University of Miami.
Don't miss out on more Redefining Medicine podcast - Subscribe today and say hello to us on social media! Email us at [email protected]
The views and opinions expressed on this program are those of the persons appearing on the program and do not necessarily reflect the views and opinions of The American Academy of Anti-Aging Medicine A4M/MMI™